Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2R2: Higher Dose Rifampin for Latent TB
NCT03988933Phase 2Completed
- Sponsor
- McGill University Health Centre
- Start
- Sep 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of rifampicin in Tuberculosis (TB), sponsored by McGill University Health Centre. Started Sep 2019; status: completed.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03988933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988933.